---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-103957"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2024-09-05T23:59:59+00:00"
generated_at: "2026-05-31T06:17:21.028857+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Galecto effectuates 1-for-25 reverse stock split effective August 29, 2024

## Summary
- Stockholders approved reverse split at June 20 special meeting; board set ratio at 1-for-25.
- Every 25 pre-split shares converted into 1 share; fractional shares rounded up to whole share.
- Outstanding stock options and equity plans proportionately adjusted; trading symbol GLTO unchanged.
- New CUSIP number is 36322Q 206; split effective after market close on August 29, 2024.

## SEC filing metadata
- accession: 0000950170-24-103957
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2024-09-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000095017024103957/0000950170-24-103957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000095017024103957/glto-20240829.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-103957
- JSON: https://secwatch.observer/filing/0000950170-24-103957.json
- Plain text: https://secwatch.observer/filing/0000950170-24-103957.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.